Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Celecoxib in Advanced Non-Small Cell Lung Cancer
NCT00062101Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2004
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib and celecoxib oral solution in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 5 years. Started Jan 2004; status: completed.
02
Drugs
erlotinibcelecoxib oral solution
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00062101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062101.